Pink SheetWhen it comes to ALS drugs, it is safe to say that there is no such thing as a routine regulatory review at the US Food & Drug Administration. The latest development in the field – FDA’s acceptance of
ScripOtsuka Pharmaceutical Co. Ltd. ’s Abilify (aripiprazole) is encountering its biggest threat so far in China, as other local versions of the once best-selling schizophrenia drug have been included in t
Pink SheetThe US Supreme Court’s unanimous decision that the Federal Trade Commission does not have the authority to seek monetary relief such as restitution or disgorgement in litigation eliminates the agency’
Generics BulletinTeva and its Cephalon affiliate have received fines totaling €60.5m ($72m) from the European Commission over an historic ‘pay-for-delay’ arrangement covering Cephalon’s Provigil (modafinil) that vi